OCULIS Aktie

 

ZUG, Switzerland, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company....

The consensus price target hints at a 106% upside potential for Oculis Holding AG (OCS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term....

ZUG, Switzerland, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company....

Oculis Holding AG (OCS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

ZUG, Switzerland, Nov. 28, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company....

ZUG, Switzerland, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company's Board of Directors....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the third quarter ended September 30, 2025, and provided an overview of the Company's progress....

ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, announced today that Oculis' management will participate in upcoming investor conferences in November....

ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.25 per share for total gross proceeds of $110 million before deducting underwriting discounts and commissions and offering expenses. In connection with the Underwritten Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 703,703 ordinary shares at a price of $20.25 per share....

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The attached two notifications relate to the exercise of vested stock options to purchase ordinary shares previously granted to a director of the Company, and the subsequent sale of those ordinary shares. These transactions were entered into pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended....

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis' innovative late-stage pipeline will be highlighted at Eyecelerator and at the American Academy of Ophthalmology (AAO) Annual Meeting....

ZUG, Switzerland, Oct. 08, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company....

ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)...

Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)...

ZUG, Switzerland, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended....

Oculis Holding AG (OCS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term....

Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial...

ZUG, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company....

ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced, in collaboration with EURETINA, the winner of the Ramin Tadayoni Award 2025....